TG 4023

Drug Profile

TG 4023

Alternative Names: Ad-FCU1; MVA-FCU1; TG4023

Latest Information Update: 03 Nov 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Transgene
  • Class Antineoplastics; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Colorectal cancer; Hepatocellular carcinoma

Most Recent Events

  • 02 Nov 2011 TG 4023 is still in phase I trials for Liver cancer in France
  • 04 Nov 2009 Phase-I clinical trials in Hepatocellular carcinoma cancer in France (Intratumoural)
  • 17 Sep 2009 Preclinical trials in Colorectal cancer in France (Intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top